___

• [1] Agosto, L. M., Zhong, P., Munro, J. and Mothes, W. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog, 10, e1003982 (2014).
• [2] Arlinghaus, S. Practical handbook of curve fitting. CRC press (1994).
• [3] Boccia, A., Falugi, P., Maurer, H. and Vinter, R. B. Free time optimal control problems with time delays. In Decision and Control (CDC), 2013 IEEE 52nd Annual Conference, 520-525 (2013).
• [4] Bonhoeffer, S., Coffin, J. M. and Nowak, M. A. Human immunodeficiency virus drug therapy and virus load. Journal of Virology, 71(4),3275-3278 (1997).
• [5] Burden, T. N., Ernstberger, J. and Fister, K. R. Optimal control applied to immunotherapy. Discrete and Continuous Dynamical Systems Series B, 4(1), 135-146 (2004).
• [6] Butler, S., Kirschner, D. and Lenhart, S. Optimal control of chemotherapy affecting the infectivity of HIV. Ann Arbor, 1001, 48109- 0620 (1997).
• [7] Cai, L., Guo, S. and Wang, S. Analysis of an extended HIV/AIDS epidemic model with treatment. Applied Mathematics and Computation, 236, 621-627 (2014).
• [8] Callaway, D. S. and Perelson, A. S. HIV-1 infection and low steady state viral loads. Bulletin of mathematical biology, 64(1), 29-64 (2002).
• [9] Cassels, S., Jenness, S. M. and Khanna, A. S. Conceptual Framework and Research Methods for Migration and HIV Transmission Dynamics. AIDS and Behavior, 18(12), 2302- 2313 (2014).
• [10] Cheney, E. and Kincaid, D. Numerical mathematics and computing. Cengage Learning, (2012).
• [11] Coffin, J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science, 267(5197), 483-489 (1995).
• [12] Culshaw, R. V. and Ruan, S. A delaydifferential equation model of HIV infection of CD4+ T-cells. Mathematical biosciences, 165(1), 27-39 (2000).
• [13] Culshaw, R. V., Ruan, S. and Spiteri, R. J. Optimal HIV treatment by maximising immune response. Journal of Mathematical Biology, 48(5), 545-562 (2004).
• [14] Elmouki, I., Saadi, S. Quadratic and linear controls developing an optimal treatment for the use of BCG immunotherapy in superfi- cial bladder cancer. Optimal Control Applications and Methods. (2015).
• [15] Elmouki, I., Saadi, S. BCG immunotherapy optimization on an isoperimetric optimal control problem for the treatment of superfi- cial bladder cancer. International Journal of Dynamics and Control. 1-7, (2014).
• [16] Fauci, A.S., Desrosiers, R.C. Pathogenesis of HIV and SIV, 587-636. Cold Spring Harbor Laboratory Press, New York (1997).
• [17] Fleming, W.H., Rishel, R.W. Deterministic and stochastic optimal control. Springer Verlag, New York (1975).
• [18] Gray, C.M., Lawrence, J., Schapiro, J.M., Altman, J.D., Winters, M.A., Crompton, M., Loi, M., Kundu, S.K., Davis, M.M. and Merigan, T.C. Frequency of Class I HLARestricted anti-HIV CD8+ T-cells in individuals receiving Highly Active Antiretroviral Therapy (HAART). The journal of immunology. 162, 1780-1788 (1999).
• [19] Gumel, A.B. Spread and control of HIV: a mathematical model. Accromath. 26(8), (2013).
• [20] Hamdache, A., Saadi, S., Elmouki, I., Zouhri, S. Two Therapeutic Approaches for the Treatment of HIV Infection in AIDS Stage. Journal of Applied Mathematical sciences. 7(105), 5243-5257 (2013).
• [21] Hamdache, A., Elmouki, I., Saadi, S. Optimal Control with an Isoperimetric Constraint Applied to Cancer Immunotherapy. International Journal of Computer Applications. 94(15), 31-37 (2014).
• [22] Hamdache, A., Saadi, S. and Elmouki, I. Nominal and neighboring-optimal control approaches to the adoptive immunotherapy for cancer. International Journal of Dynamics and Control, 1-16 (2015).
• [23] Hlavacek, W.S., Wofsy, C. and Perelson, A.S. Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proceedings of the National Academy of Sciences. 96(26), 14681-14686 (1999).
• [24] Iversen, A.K., Shafer, R.W., Wehrly, K., Winters, M.A., Mullins, J.I., Chesebro, B. and Merigan, T.C. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Journal of Virology. 70(2), 1086- 1090 (1996).
• [25] Jacobson, E.L., Pilaro, F. and Smith, A.K. Rationnal IL-2 therapy for HIV positifs individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci USA. 93, 10405-10410 (1996).
• [26] Janeway, C., Murphy, K. P., Travers, P. and Walport, M. Janeway's immunobiology, 530- 535. Garland Science, London (2008).
• [27] Jang, T., Kwon, H. D. and Lee, J. Free terminal time optimal control problem of an HIV model based on a conjugate gradient method. Bulletin of mathematical biology, 73(10), 2408-2429 (2011).
• [28] Jiang, C., Lin, Q., Yu, C., Teo, K. L. and Duan, G. R. An exact penalty method for free terminal time optimal control problem with continuous inequality constraints. Journal of Optimization Theory and Applications, 154(1), 30-53 (2012).
• [29] Joshi, H. R. Optimal control of an HIV immunology model. Optimal control applications and methods, 23(4), 199-213 (2002).
• [30] Kirschner, D.E., Webb, G.F. Immunotherapy of HIV-1 infection. Journal of Biological Systems. 6(1), 71-83 (1998).
• [31] Khanna, A. S., Dimitrov, D. T. and Goodreau, S. M. What can mathematical models tell us about the relationship between circular migrations and HIV transmission dynamics?. Mathematical biosciences and engineering: MBE, 11(5), 1065-1090 (2014).
• [32] Klatzmann, D. and Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nature Reviews Immunology, (2015).
• [33] Lenhart, S., Workman, T. Optimal control applied to biological models, 49-55. Chapman and Hall/CRC Mathematical and Computational Biology Series, New York (2007).
• [34] L´evy, Y. Immunoth´erapie de l'infection par le VIH par l'utilisation de cytokines: un ´etat des lieux. M/S: m´edecine sciences. 22(8-9), 751-754 (2006).
• [35] Lukes, D. L. Differential Equations: Classical to Controlled, Mathematics in Science and Engineering, Academic Press, New York, (1982).
• [36] Maartens, G., Celum, C. and Lewin, S. R. HIV infection: epidemiology, pathogenesis, treatment, and prevention. The Lancet, 384(9939), 258-271 (2014).
• [37] MacArthur, R.D., Novak, R.M. Maraviroc: The First of a New Class of Antiretroviral Agents. Oxford journals. 47(2), 236-241 (2008).
• [38] McAsey, M., Mou, L., Han, W. Convergence of the Forward-Backward Sweep Method in optimal control. Comput Optim Appl. 3, (2012).
• [39] Mastroberardino, A., Cheng, Y., Abdelrazec, A. and Liu, H. Mathematical modeling of the HIV/AIDS epidemic in Cuba. International Journal of Biomathematics, 1550047 (2015).
• [40] Merry, C., Barry, M.G., Mulcahy, F., Ryan, M., Heavey, J., Tjia, J.F., Gibbons, S.E., Breckenridge, A.M. and Back, D.J. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 11(4), (1997).
• [41] Palanki, S., Kravaris, C. and Wang, H. Y. Optimal feedback control of batch reactors with a state inequality constraint and free terminal time. Chemical engineering science, 49(1), 85-97 (1994).
• [42] Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. and Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 271(5255), 1582-1586 (1996)
• [43] Perelson, A. S., Kirschner, D. E. and De Boer, R. Dynamics of HIV infection of CD4+ T cells. Mathematical biosciences, 114(1), 81- 125 (1993).
• [44] Pontryagin, L. S. Mathematical theory of optimal processes. CRC Press, (1987).
• [45] Pontryagin, L. S., Boltyanskii, V. G. and Gamkrelidze, R. V. EF Mishchenko The Mathematical Theory of Optimal Processes. New York: Interscience (1962).
• [46] Pooseh, S., Almeida, R. and Torres, D. F. Fractional order optimal control problems with free terminal time. arXiv preprint arXiv: 1302.1717 (2013).
• [47] Qun, L., Loxton, R., Teo, K. L. and Wu, Y. H. A new computational method for a class of free terminal time optimal control problems. Pacific Journal of Optimization. 7(1), 63-81 (2011).
• [48] Raffi, F.: Enfuvirtide, premier inhibiteur de fusion dans le traitement de l'infection par le virus de l'immunod´eficience humaine: m´ecanisme d'action et pharmacocintique. M´edecine et maladies infectieuses. 34, 3-7 (2004).
• [49] Roshanfekr, M., Farahi, M. H. and Rahbarian, R. A different approach of optimal control on an HIV immunology model. Ain Shams Engineering Journal, 5(1), 213-219 (2014).
• [50] Roy, P.K., Chatterjee, A.N. T-cell proliferation in a mathematical model of CTL activity through HIV-1 infection. Proceedings of the World Congress on Engineering. 1, (2010).
• [51] Roy, P. K., Saha, S. and Al Basir, F. Effect of awareness programs in controlling the disease HIV/AIDS: an optimal control theoretic approach. Advances in Difference Equations, 2015(1), 1-18 (2015).
• [52] Saadi, S., Elmouki, I. and Hamdache, A. Impulsive control dosing BCG immunotherapy for non-muscle invasive bladder cancer. International Journal of Dynamics and Control, 1-11 (2015).
• [53] Stengel, R. F., Ghigliazza, R. M. and Kulkarni, N. V. Optimal enhancement of immune response Bioinformatics,18(9), 1227- 1235 (2002).
• [54] Su, B., Lederle, A., Laumond, G., Schmidt, S., Decoville, T., Ducloy, C. and Moog, C. Antibody Inhibition of HIV-1 Transmission from Antigen-presenting Cells to CD4 T Lymphocytes Involves Immune Cell Activation. AIDS research and human retroviruses, 30(S1), A154-A154 (2014).
• [55] Tr´elat, E. Controle optimal: th´eorie et applications. Paris: Vuibert (2005).
• [56] Wang, L. and Li, M. Y. Mathematical analysis of the global dynamics of a model for HIV infection of CD4+ T-cells. Mathematical Biosciences, 200(1), 44-57 (2006).
• [57] Zhou, X., Song, X. and Shi, X. A differential equation model of HIV infection of CD4+ Tcells with cure rate. Journal of Mathematical Analysis and Applications, 342(2), 1342-1355 (2008).
• [58] Zurakowski, R. and Teel, A. R. A model predictive control based scheduling method for HIV therapy. Journal of Theoretical Biology, 238(2), 368-382 (2006).